%0 Journal Article
%T Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
%A Min-Wei Huang
%A Tsung-Tsair Yang
%A Po-Ren Ten
%A Po-Wen Su
%A Bo-Jian Wu
%A Chin-Hong Chan
%A Tsuo-Hung Lan
%A I-Chao Liu
%A Wei-Cheh Chiu
%A Chun-Ying Li
%A Kuo-Sheng Cheng
%A Yu-Chi Yeh
%J BMC Pharmacology and Toxicology
%D 2012
%I BioMed Central
%R 10.1186/1472-6904-12-1
%X This was a 12-week multicenter, open-label, prospective clinical study conducted in in-patient and out-patient populations. Flexible dosing in the range 3-12 mg/day was used throughout the study. All subjects attended clinic visits on weeks 0, 4, 8, and 12 as usual clinical practice for the 12-week observation period. Data were summarized with respect to demographic and baseline characteristics, efficacy measurement with PANSS scale, PSP, and social functioning score, and safety observations. Descriptive statistics were performed to identify the retention rate at each visit as well as the symptomatic remission rate. Summary statistics of average doses the subjects received were based on all subjects participating in the study.A total of 480 patients were enrolled. Among them, 426 patients (88.8%) had evaluation at week 4 and 350 (72.9%) completed the 12-week evaluation. Patients with at least moderate severity of schizophrenia were evaluated as "mild" or better on PANSS scale by all 8 items after 12 weeks of treatment with paliperidone ER. There was significant improvement in patients' functionality as measured by PSP improvement and score changes. Concerning the other efficacy parameters, PANSS total scale, PSP total scale, and social functioning total scale at the end of study all indicated statistically significant improvement by comparison with baseline. The safety profile also demonstrated that paliperidone ER was well-tolerated without clinically significant changes after treatment administration.Although the short-term nature of this study may limit the potential for assessing improvements in function, it is noteworthy that in the present short-term study significant improvements in patient personal and social functioning with paliperidone ER treatment were observed, as assessed by PSP scale.Clinical Trials. PAL-TWN-MA3Schizophrenia is a severe form of mental illness affecting about 24 million people worldwide (7 per 1000 adult population), mostly in the age
%U http://www.biomedcentral.com/1472-6904/12/1